The move: Moderna stock popped, before paring losses as investors eye it as a play on the emerging hantavirus threat. Shares opened Monday's session higher, with the stock peaking around 22% from ...

Moderna Inc. said it’s researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.

Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...

April 24 (Reuters) - German biotech company CureVac sued Moderna (MRNA.O), opens new tab in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac ...

Moderna’s first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitted a flu vaccine candidate to regulators. But Moderna ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...

Feb 19 (Reuters) - German biopharmaceutical company BioNTech (22UAy.DE), opens new tab sued Moderna (MRNA.O), opens new tab in Delaware federal court on Thursday, alleging that Moderna's COVID-19 shot ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna's new flu vaccine after all, resolving a dispute that had blocked the company's application for the first-of ...